Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vince and Associates Clinical Research Joins the Altasciences Group

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.

Based in Overland Park, Kansas since 2001, Vince and Associates has become an established industry leader in the successful recruitment and retention of special populations in complex early development clinical trials. The Vince and Associates approach, where study teams are led by highly experienced Principal Investigators intricately involved in all aspects of the clinical trial process, has generated significant industry demand for their services from both large pharmaceutical and biotechnology clients.

“We continue to benefit from the industry shift towards these types of complex studies and joining the Altasciences team will significantly enhance our capabilities while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients,” said Dr. Brad Vince, Founder, President and Medical Director of Vince and Associates. Dr. Vince will continue to act as the CEO and Medical Director.

Altasciences, owned by Kilmer Capital Partners, also owns Algorithme Pharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and Algorithme Pharma operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!